CC-10004

Phase 2Small molecule

Amgen

CC-10004 is one of 69 small molecule programs targeting Chronic Prostatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic ProstatitisActive, not recruiting

PsoriasisActive, not recruiting

Prurigo NodularisActive, not recruiting

Chronic ProstatitisPhase 2

Active, not recruiting

PsoriasisPhase 2

Active, not recruiting

Prurigo NodularisPhase 2

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

Cosentyx

Novartis

Preclinical

53 2

Taltz

Eli Lilly

Preclinical

20 3

Bimzelx

UCB

Preclinical

17 4

Humira

CCelltrion

Preclinical

42 5

Ilumya

Sun Pharmaceutical Industries, Inc.

Preclinical

15 6

Raptiva

Roche

Preclinical

10 7

Remicade

OOrganon and Co

Preclinical

20 8

Siliq

BBausch Health Americas, Inc.

Preclinical

14 9

Lovenox

Sanofi

Preclinical

1 10

CC-10004

Amgen

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prurigo Nodularis1 trial

Safety and Efficacy of CC-10004 for Prurigo Nodularis

Completed·UUniversity Hospitals Cleveland Medical Center·Phase 2·NCT00869089·5 enrolled

Chronic Prostatitis1 trial

An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Completed·KKenneth Peters, MD·Phase 2·NCT00701311·21 enrolled

ESS1 trial

Expanded Access for CC-10004

No longer available· Amgen logo

Amgen··NCT03740516

Immune1 trial

Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients

Completed·NNYU Langone Health·Phase 1/2·NCT00708916·8 enrolled

Vulvodynia1 trial

CC-10004 For The Treatment Of Vulvodynia

Completed·KKenneth Peters, MD·Phase 2·NCT00814632·10 enrolled

1 more indication

Psoriasis1 trial

Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis

Completed· Amgen logo

Amgen·Phase 2·NCT00606450·260 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for CC-10004. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CC-10004 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CC-10004. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Amgen

CC-10004

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prurigo Nodularis1 trial

Chronic Prostatitis1 trial

ESS1 trial

Immune1 trial

Vulvodynia1 trial

Psoriasis1 trial

References

Drug Info

Quick Facts

Related News